Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (JAZZ) to Hold on Xyrem Risk
Tweet Send to a Friend
Cantor Fitzgerald downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Hold with a price target of $182.00 (from $170.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
